DurAVR® THV Medium Valve Data at TCT 2026

At TCT, Dr. Azeem Latib presented the first look at 30-day data from patients treated with the Medium DurAVR® THV in the EMBARK Study.

Highlights of 30-day outcomes for the Medium DurAVR® THV

Favorable hemodynamics through 30 days with single-digit mean gradient and large EOA
Met safety endpoints for outcomes at 30 days
No moderate or severe PVL or PPM at 30 days